In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, [Read More…]
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The study discovered that the body may produce more ID3+ T cells in response to certain signals, opening the door for better therapies like CAR T cell therapy.
In order to build the groundwork for creating CAR molecules that optimize antitumor activity beyond B cell malignancies, researchers set out to comprehend how CAR T cells with various signaling domains function at the molecular and cellular levels.
CAR T cell therapy allows a patient’s T cells to be reprogrammed to identify and eliminate the cancer cells
